UBS Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-47,824
| Closed | -$2.3M | – | 7650 |
|
|
2020
Q1 | $2.3M | Buy |
47,824
+28,292
| +145% | +$1.36M | ﹤0.01% | 2067 |
|
|
2019
Q4 | $917K | Sell |
19,532
-92,349
| -83% | -$4.34M | ﹤0.01% | 3418 |
|
|
2019
Q3 | $2.65M | Buy |
111,881
+86,337
| +338% | +$2.04M | ﹤0.01% | 2388 |
|
|
2019
Q2 | $768K | Buy |
25,544
+23,716
| +1,297% | +$713K | ﹤0.01% | 3227 |
|
|
2019
Q1 | $41K | Buy |
1,828
+198
| +12% | +$4.44K | ﹤0.01% | 4893 |
|
|
2018
Q4 | $30K | Buy |
+1,630
| New | +$30K | ﹤0.01% | 5583 |
|
|
2018
Q3 | – | Sell |
-5,171
| Closed | -$51K | – | 7311 |
|
|
2018
Q2 | $51K | Sell |
5,171
-43,582
| -89% | -$430K | ﹤0.01% | 5053 |
|
|
2018
Q1 | $259K | Buy |
+48,753
| New | +$259K | ﹤0.01% | 3834 |
|
|
2017
Q4 | – | Sell |
-393
| Closed | -$6K | – | 7092 |
|
|
2017
Q3 | $6K | Sell |
393
-65,241
| -99% | -$996K | ﹤0.01% | 6257 |
|
|
2017
Q2 | $1.23M | Buy |
65,634
+64,169
| +4,380% | +$1.2M | ﹤0.01% | 2764 |
|
|
2017
Q1 | $31K | Sell |
1,465
-926
| -39% | -$19.6K | ﹤0.01% | 4940 |
|
|
2016
Q4 | $36K | Buy |
+2,391
| New | +$36K | ﹤0.01% | 5176 |
|